Treat-to-target: Rationale and strategies

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Smolen, J S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Quality of life; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ARTICLE; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; WELLBEING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PATIENT CARE PLANNING; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84870288740     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. WARRAM JH, MANSON JE, KROLEWSKI AS: Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1305-6.
2. EEG-OLOFSSON K, CEDERHOLM J, NILS-SON PM, GUDBJORNSDOTTIR S, ELIASSON B: Glycemic and risk factor control in type 1 diabetes: results from 13, 612 patients in a national diabetes register. Diabetes Care 2007;30:496-502.
3. EGAN BM, LACKLAND DT, CUTLER NE: Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research. Arch Intern Med 2003;163:681-7.
4. CONROY RM, PYORAL A K, FITZGERALD AP et al:. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
5. RIDKER PM: Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Curr Alheroscler Rep 2009;11:249-56.
6. PINCUS T, GIBOFSKY A, WEINBLATT ME: Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002;46:851-4.
7. SMYTHE HA, HELEWA A, GOLDSMITH CH: "Independent assessor" and "pooled index" as techniques for measuring treatment effects in rheumatoid arthritis. J Rheumatol 1977;4:144-52.
8. GOLDSMITH CH, SMYTHE HA, HELEWA A: Interpretation and power of a pooled index. J Rheumatol 1993;20:575-8.
9. VAN Der HEIJDE DM, VAN RIEL PL, VAN LEEU-WEN MA, VAN 'T HOF MA, VAN RIJSWIJK MH, van de PUTTE LB: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
10. VAN Der HEIJDE DM, VAN'T HOF MA, VAN RIEL PL, VAN LEEUWEN MA, VAN RIJSWIJK MH, van DE PUTTE LB: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
11. VAN LEEUWEN MA, VAN der HEIJDE DM, VAN RIJSWIJK MH et al:. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
12. SMOLEN JS, BREEDVELD FC, SCHIFF MH et al:. A Simplified Disease Activity Index for Rheumatoid Arthritis For Use In Clinical Practice. Rheumatology 2003;42:244-57.
13. SCHOELS M, ALETAHA D, FUNOVITS J, KAVANAUGH A, BAKER D, SMOLEN JS: Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
14. MACHADO P, LANDEWÉ R, LIE E et al:. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
15. PEDERSEN SJ, SORENSEN IJ, HERMANN KG et al:. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065-71.
16. WOLFE F, PINCUS T: The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001;28:1817-24.
17. SOKKAT, PINCUS T: Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009;36:1387-90.
18. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
19. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
20. PINCUS T, WOLFE F: An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. (Editorial). J Rheumatol 2000;27:2727-30.
21. WARE JE J, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
22. ALETAHA D, SMOLEN J, WARD MM: Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
23. SMOLEN JS, ALETAHA D: The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2010;28(Suppl. 59):S18-S27.
24. SMOLEN JS, ALETAHA D, GRISAR JC, STAMM TA, SHARP JT: Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69:1058-64.
25. VAN Der HEIJDE D, LANDEWÉ R, VAN VOL-LENHOVEN R, FATENEJAD S, KLARESKOG L: Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-70.
26. SMOLEN JS, VAN der HEIJDE DMFM, ST. CLAIR EW et al:. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the AS-PIRE trial. Arthritis Rheum 2006;54:702-10.
27. ALETAHA D, NELL VPK, STAMM T et al:. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res 2005;7:R796-R806.
28. RADNERH, SMOLEN JS, ALETAHA D: Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:536-541.
29. ALETAHA D, WARD MM: Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
30. VAN GESTEL AM, PREVOO MLL, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LBA, van RIEL PLCM: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
31. ALETAHA D, WARD MM, MACHOLD KP, NELL VPK, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
32. SMOLEN JS, HAN C, VAN der HEIJDE DM et al:. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis 2009;68:823-7.
33. KLARENBEEK NB, KOEVOETS R, VAN der HEIJDE DM et al:. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EU-LAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011;70:1815-21.
34. PUOLAKKA K, KAUTTIAINEN H, MÖTTÖNEN T et al:. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005;64:130-3.
35. FELSON DT, SMOLEN JS, WELLS G et al:. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
36. SMOLEN JS, HAN C, BALA M et al:. Evidence of Radiographic Benefit of Infliximab Plus Methotrexate in Rheumatoid Arthritis Patients Who Had No Clinical Improvement: A Detailed Subanalysis of the ATTRACT Trial. Arthritis Rheum 2005;52:1020-30.
37. LANDEWÉ R, VAN der HEIJDE D, KLARESKOG L, VAN VOLLENHOVEN R, FATENEJAD S: Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
38. SMOLEN JS, MARTINEZ-AVILA JC, ALETAHA D: Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its antiinflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012;71:687-93.
39. ALETAHA D, FUNOVITS J, SMOLEN JS: The importance of reporting disease activity states in clinical trials of rheumatoid arthritis. Arthritis Rheum 2008;58:2622-31.
40. GRIGOR C, CAPELL H, STIRLING A et al:. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
41. GOEKOOP-RUITERMAN YP, DE VRIES-BOU-WSTRA JK, KERSTENS PJ et al:. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
42. VERSTAPPEN SMM, JACOBS JWG, VAN der VENN MJ et al:. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
43. BARKER MF, JACOBS JW, WELSING PM et al.: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A Randomized Trial. Ann Intern Med 2012;156:329-39.
44. SCHOELS M, KNEVEL R, ALETAHA D et al.: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
45. BARKER MF, CAVET G, JACOBS JW et al.: Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012.
46. DE VRIES-BOUWSTRA JK, GOEKOOP-RUITER-MEN YPM, VAN ZEBEN D, BREEDVELD FC, DIJKMANS BAC, HAZES JMW: A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: Results of the Best trial. Ann Rheum Dis 2004;63(Suppl. 1): 58):58 (Abstract).
47. SMOLEN JS, LANDEWE R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
48. VAN Der HEIDE A, JACOBS JW, BIJLSMA JW et al.: The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
49. LARD LR, VISSER H, SPEYER I et al.: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
50. NELL V, MACHOLD KP, EBERL G, STAMM TA, UFFMANN M, SMOLEN JS: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14.
51. ALETAHA D, NEOGI T, SILMAN A et al.: The 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis. Ann Rheum Dis 2010;69:1580-8.
52. EMERY P, BREEDVELD FC, DOUGADOS M, KALDEN JR, SCHIFF MH, SMOLEN JS: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
53. GARTNER M, FABRIZII JP, KOBAN E et al.: Immediate access rheumatology clinic: efficiency and outcomes. Ann Rheum Dis 2012;71:363-8.
54. SMOLEN JS, ALETAHA D, BIJLSMA JWJ, et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
55. KLARENBEEK NB, GULER-YUKSEL M, VAN der HEIJDE DM et al.: Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann Rheum Dis 2010;69:2107-13.
56. WOLFE F: A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61.
57. PINCUS T, BROOKS RH, CALLAHAN LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
58. SINGH JA, FURST DE, BHARA TA et al.: 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
59. HARAOUI B, SMOLEN JS, ALETAHA D et al.: Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011;70:1999-2002.
60. DE WIT M, SMOLEN JS, GOSSEC L, VAN der HEIJDE D: Treating rheumatoid arthritis to target: The patient version of the international recommendations. Ann Rheum Dis 2011;70:891-5.
61. MICHAUD K, WOLFE F: Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:885-906.
62. RADNER H, SMOLEN JS, ALETAHA D: Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:381-8.